Chair, American Clinicians Academy on Medical Aid in Dying.
Mitchell Hamline School of Law.
Am J Bioeth. 2023 Sep;23(9):5-15. doi: 10.1080/15265161.2022.2105422. Epub 2022 Aug 16.
Terminally ill patients in 10 states plus Washington, D.C. have the right to take prescribed medications to end their lives (medical aid in dying). But otherwise-eligible patients with neuromuscular disabilities (ALS and other illnesses) are excluded if they are physically unable to "self-administer" the medications . This exclusion is incompatible with disability rights laws that mandate assistance to provide equal access to health care. This contradiction between aid-in-dying laws and disability rights laws can force patients and clinicians into violating one or the other, potentially creating an underclass of patients denied medical care that is available to those with other (less physically disabling) terminal illnesses. The immediacy of this issue is demonstrated by a lawsuit in Federal court filed in August 2021, requesting assistance in self-administration for terminally ill patients with neuromuscular diseases. This paper discusses the background of this conflict, the ethical issues at the heart of the dilemma, and recommends potential remedies.
10 个州加上华盛顿特区的绝症患者有权服用规定的药物来结束自己的生命(医疗辅助自杀)。但是,如果患有神经肌肉疾病(ALS 和其他疾病)的其他符合条件的患者由于身体无法“自行给药”而被排除在外。这种排除与要求提供协助以平等获得医疗保健的残疾权利法相冲突。协助自杀法与残疾权利法之间的这种矛盾可能迫使患者和临床医生违反其中一项法律,从而有可能制造出一个被剥夺医疗的病人阶层,而这些病人本可以获得其他(身体残疾程度较低的)绝症患者所拥有的医疗服务。2021 年 8 月在联邦法院提起的一起诉讼突显了这个问题的紧迫性,该诉讼要求为患有神经肌肉疾病的绝症患者提供自我管理方面的协助。本文讨论了这一冲突的背景、困境核心的伦理问题,并提出了潜在的补救措施。